In lung adenocarcinoma, patients with increased COPB2 expression showed advanced clinical symptoms more often, such as low pathological grade, presence of lymph node metastasis, higher TNM stage, presence of distant metastasis, and worse overall survival [2]. Here, COPB2 is linked to metastatic malignant neoplasm in the lymph nodes.